Montag & Caldwell LLC Trims Position in IQVIA Holdings Inc. (NYSE:IQV)

Montag & Caldwell LLC lessened its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 74.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 13,090 shares of the medical research company's stock after selling 38,012 shares during the quarter. Montag & Caldwell LLC's holdings in IQVIA were worth $2,572,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Synergy Asset Management LLC acquired a new stake in IQVIA during the 4th quarter valued at approximately $33,000. Lee Danner & Bass Inc. acquired a new position in shares of IQVIA in the fourth quarter worth about $44,000. Zions Bancorporation N.A. increased its stake in shares of IQVIA by 55.2% in the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after purchasing an additional 85 shares in the last quarter. Versant Capital Management Inc boosted its position in IQVIA by 46.0% during the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock worth $58,000 after purchasing an additional 93 shares in the last quarter. Finally, SBI Securities Co. Ltd. acquired a new stake in IQVIA in the fourth quarter valued at approximately $60,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Down 3.2 %

Shares of IQV traded down $4.78 during midday trading on Friday, reaching $143.66. The stock had a trading volume of 3,302,597 shares, compared to its average volume of 1,403,069. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The company's fifty day simple moving average is $177.57 and its two-hundred day simple moving average is $197.47. The company has a market cap of $25.33 billion, a price-to-earnings ratio of 19.15, a PEG ratio of 1.99 and a beta of 1.46. IQVIA Holdings Inc. has a 1-year low of $135.97 and a 1-year high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on IQV shares. Royal Bank of Canada reissued an "outperform" rating and issued a $270.00 price target on shares of IQVIA in a research note on Monday, February 10th. JPMorgan Chase & Co. decreased their price target on shares of IQVIA from $240.00 to $232.00 and set an "overweight" rating on the stock in a research note on Tuesday, February 18th. BTIG Research downgraded IQVIA from a "buy" rating to a "neutral" rating in a research report on Monday, February 3rd. UBS Group reduced their price objective on IQVIA from $260.00 to $255.00 and set a "buy" rating for the company in a research note on Friday, February 7th. Finally, Robert W. Baird decreased their price target on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 21st. Six equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $241.50.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.